Skip to content
naulon
Not checkedNot checked for notices yet.

CHARACTERIzATION of CD4 + T LYMPHOCYTE FROM BONE MAROW STEM CELL USING INDIRECT IMMUNOFLUORESENCE FOR HIV & AIDS TREATMENT

Purwati Purwati, Nasronudin Nasronudin, Fedik Abdul Rantam

Indonesian Journal of Tropical and Infectious Disease · 2010

doi:10.20473/ijtid.v1i3.2195 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Acquired immune deficiency syndrome (AIDS) is caused by Human Immunodeficiency Virus (HIV). At the beginning of infection, gp120 virus interacts with CD4 receptor at the surface of the target cell. The interaction between gp120 and CD4 leads to the occurrence of the binding of specific chemokine receptor CXCR4 and CCR5, which are also present on the membrane of the target cell. Therefore, CCR5 and CXCR4 also determine the fate of the target cell. It is the performance of CCR5 and CXCR4, guided by controlling gene that determines susceptibility or resistance to HIV infection. Coding gene CCR5 may mutate to become protective or resistant against HIV infection. In homozygote individuals, it tends to be resistant against infection, while in heterozygote individuals it tends to be susceptible to HIV infection. Objective: To characterize TCD4 lymphocyte in the next that is resistant against HIV infection by using gene therapy deletion 32 CCR5 to use for HIV & AIDS treatment. Method: Sample collection, mononucleated cell collection, lymphocyte culture, CD4 identification, CCR5 variance analysis, co-cultivation with PBMC HIV and comparison to control. Result: This study was performed in several steps, such as mononucleated cell isolation, followed with cell culture, lymphocyte purification, lymphocyte and CD4 expression identification. Conclusion: Lymphocyte T CD4 had been mature after seven passages, once passage is about 5 days so for maturity lymphocyte T CD4 need 35 days and that cell as be candidate to resistant against HIV infection by using gene therapy deletion 32 CCR5 to use for HIV & AIDS treatment.

Abstract licence: CC BY-NC-SA

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.